AMARIN CORPORATION PLC - AMERICAN DEPOSITARY SHARE

Amarin Board of Directors Announces CEO Transition

04 يونيو 2024 06:30:00 بحسب Nasdaq GlobeNewswire

 Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.

28 مايو 2024 07:15:23 بحسب Nasdaq GlobeNewswire

Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference

06 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

 Amarin Reports First Quarter 2024 Business Update and Financial Results

01 مايو 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

24 أبريل 2024 13:00:01 بحسب Nasdaq GlobeNewswire

Amarin Announces Results of Annual General Meeting of Shareholders

22 أبريل 2024 07:00:25 بحسب Nasdaq GlobeNewswire

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

15 أبريل 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

08 أبريل 2024 07:00:01 بحسب Nasdaq GlobeNewswire

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

06 أبريل 2024 14:30:00 بحسب Nasdaq GlobeNewswire

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

03 أبريل 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo

25 مارس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

29 فبراير 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024

15 فبراير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Amarin Chairman & CEO Issue Letter to Shareholders

22 يناير 2024 06:30:00 بحسب Nasdaq GlobeNewswire

Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024

10 يناير 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference

11 ديسمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Amarin Reports Third Quarter 2023 Financial Results

01 نوفمبر 2023 06:00:00 بحسب Nasdaq GlobeNewswire

Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer

31 أكتوبر 2023 11:00:00 بحسب Nasdaq GlobeNewswire

Latest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023

26 أكتوبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

 Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023

19 أكتوبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire